News
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing" Novo Nordisk said it will stop selling Wegovy on ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...
Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback